INVA Insider Trading

Insider Ownership Percentage: 1.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Innoviva Insider Trading History Chart

This chart shows the insider buying and selling history at Innoviva by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Innoviva Share Price & Price History

Current Price: $18.58
Price Change: Price Increase of +0.13 (0.70%)
As of 01/17/2025 05:00 PM ET

This chart shows the closing price history over time for INVA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$18.58Closing price on 01/19/25:

Innoviva Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Innoviva (NASDAQ:INVA)

99.12% of Innoviva stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INVA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$212kbought$19ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Innoviva logo
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Read More on Innoviva

Today's Range

Now: $18.58
Low: $18.44
High: $18.61

50 Day Range

MA: $18.43
Low: $17.28
High: $20.32

52 Week Range

Now: $18.58
Low: $14.32
High: $21.28

Volume

606,495 shs

Average Volume

542,593 shs

Market Capitalization

$1.16 billion

P/E Ratio

26.93

Dividend Yield

N/A

Beta

0.54

Who are the company insiders with the largest holdings of Innoviva?

Innoviva's top insider shareholders include:
  1. Alexander J Denner (Major Shareholder)
  2. Pavel Raifeld (CEO)
Learn More about top insider investors at Innoviva.

Who are the major institutional investors of Innoviva?

Innoviva's top institutional investors include:
  1. Ritholtz Wealth Management — 0.12%
  2. CWA Asset Management Group LLC — 0.06%
  3. Everence Capital Management Inc. — 0.02%
Learn More about top institutional investors of Innoviva stock.

Which institutional investors are selling Innoviva stock?

In the last quarter, INVA stock was sold by these institutional investors:
  1. Everence Capital Management Inc.

Which institutional investors are buying Innoviva stock?

In the previous quarter, INVA stock was acquired by institutional investors including:
  1. CWA Asset Management Group LLC
  2. Ritholtz Wealth Management
Within the previous year, these company insiders have bought Innoviva stock:
  1. Alexander J Denner (Major Shareholder)
  2. Pavel Raifeld (CEO)
Learn More investors buying Innoviva stock.